US FDA approves Ionis Pharma's genetic disorder drug-March 2024-www.financetom.com

US FDA approves Ionis Pharma's genetic disorder drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Ionis Pharma's genetic disorder drug

Dec 19, 2024 2:30 PM

Dec 19 (Reuters) - The U.S. Food and Drug Administration

has approved Ionis Pharmaceuticals' ( IONS ) drug to treat a

rare genetic disorder, making it the company's first wholly

owned drug, the health regulator's website showed on Thursday.

Previous page： National Bank Hikes Loblaw Target to $175, Maintains Outperform Next page： Gentex Stock Sinks 7% After Q2 Earnings Miss And Revenue Forecast Slash - Details Here

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

National Bank Hikes Loblaw Target to $175, Maintains Outperform

Jul 26, 2024

11:00 AM EDT, 07/26/2024 (MT Newswires) -- National Bank has hiked its one year target on Loblaw ( LBLCF ) to $175 (from $159), and maintained its Outperform rating. On Thursday, Loblaw ( LBLCF ) reported second quarter adjusted EPS of $2.15 versus NBF and consensus at $2.14; last year was $1.94. National Bank notes that results were mixed; sssg...

Gentex Stock Sinks 7% After Q2 Earnings Miss And Revenue Forecast Slash - Details Here

Jul 26, 2024

Gentex Corporation ( GNTX ) shares are trading lower after the company missed second-quarter earnings estimates and lowered its guidance. The company reported second-quarter earnings per share of 37 cents, but it missed the street view of 52 cents. Quarterly sales of $572.93 million missed the analyst consensus of $622.79 million. Automotive net sales were $559.3 million, down from $574.1 million in...

--Gorman-Rupp Maintains Quarterly Cash Dividend at $0.18 Per Share, Payable Sept. 10 to Shareholders of Record Aug. 15

Jul 26, 2024

11:03 AM EDT, 07/26/2024 (MT Newswires) -- Price: 41.97, Change: +1.34, Percent Change: +3.30 ...

Carter's Faces 'Major Challenges' as Drop in Sales, Margins, EPS Set to Continue, Wedbush Says

Jul 26, 2024

11:06 AM EDT, 07/26/2024 (MT Newswires) -- Carter's (CRI) is facing major challenges in business, leading to a large cut in their sales and earnings growth forecasts for fiscal year 2024, Wedbush Securities said in a note Friday. Analysts, including Tom Nikic, said that while the company's guidance for H2 of the fiscal year looks more attainable, it's hard to...